RITUXIMAB FOR THE TREATMENT OF PEMPHIGUS - A REVIEW OF RECENT STUDIES AND PERSONAL EXPERIENCE FROM THE RABIN MEDICAL CENTER AND THE SHEBA MEDICAL CENTER
INTRODUCTION: Pemphigus is a chronic autoimmune bullous disease. To date there is no curative treatment for the disease. The standard treatment has been based on systemic corticosteroids and immune-suppressants. Rituximab is a monoclonal antibody against CD20 cells which leads to B cell depletion, resulting in decreased antibody production. In recent years increasing evidence on promising efficacy and safety of rituximab in the treatment of pemphigus has emerged. This review presents the key publications and the Israeli experience with rituximab treatment at the Rabin and the Sheba Medical Centers. Disclosure: Prof. Daniel Mimouni participated in an advisory board of Roche.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:159 |
|---|---|
| Enthalten in: |
Harefuah - 159(2020), 1 vom: 13. Jan., Seite 31-33 |
| Sprache: |
Hebräisch |
|---|
| Beteiligte Personen: |
Mimouni, Daniel [VerfasserIn] |
|---|
| Themen: |
4F4X42SYQ6 |
|---|
| Anmerkungen: |
Date Completed 29.01.2020 Date Revised 29.01.2020 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM305294385 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM305294385 | ||
| 003 | DE-627 | ||
| 005 | 20231225120849.0 | ||
| 007 | tu | ||
| 008 | 231225s2020 xx ||||| 00| ||heb c | ||
| 028 | 5 | 2 | |a pubmed24n1017.xml |
| 035 | |a (DE-627)NLM305294385 | ||
| 035 | |a (NLM)31930805 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a heb | ||
| 100 | 1 | |a Mimouni, Daniel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a RITUXIMAB FOR THE TREATMENT OF PEMPHIGUS - A REVIEW OF RECENT STUDIES AND PERSONAL EXPERIENCE FROM THE RABIN MEDICAL CENTER AND THE SHEBA MEDICAL CENTER |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 29.01.2020 | ||
| 500 | |a Date Revised 29.01.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Pemphigus is a chronic autoimmune bullous disease. To date there is no curative treatment for the disease. The standard treatment has been based on systemic corticosteroids and immune-suppressants. Rituximab is a monoclonal antibody against CD20 cells which leads to B cell depletion, resulting in decreased antibody production. In recent years increasing evidence on promising efficacy and safety of rituximab in the treatment of pemphigus has emerged. This review presents the key publications and the Israeli experience with rituximab treatment at the Rabin and the Sheba Medical Centers. Disclosure: Prof. Daniel Mimouni participated in an advisory board of Roche | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Antibodies, Monoclonal, Murine-Derived |2 NLM | |
| 650 | 7 | |a Immunologic Factors |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 700 | 1 | |a Baum, Sharon |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Harefuah |d 1946 |g 159(2020), 1 vom: 13. Jan., Seite 31-33 |w (DE-627)NLM000070491 |x 0017-7768 |7 nnns |
| 773 | 1 | 8 | |g volume:159 |g year:2020 |g number:1 |g day:13 |g month:01 |g pages:31-33 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 159 |j 2020 |e 1 |b 13 |c 01 |h 31-33 | ||